Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Analyst picks & changes

Genetics Institute Inc.

(GENIZ)

Stuart Weisbrod of Merrill Lynch raised his long-term rating to "buy" from "above average"

Read the full 184 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE